Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of maribavir versus valganciclovir for asymptomatic CMV infection after HSCT
MOH_2021-10-05_010143Phase 3Not yet recruiting
- Sponsor
- Takeda
- Start
- Sep 2021
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cytomegalovirus disease (CMV) comparing Maribavir arm with Valganciclovir arm (2 arms). Primary endpoint: CMV viremia clearance at week 8. Planned start Sep 2021; status: not yet recruiting.
02
Drugs
maribavirvalganciclovir
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on MOH_2021-10-05_010143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-10-05_010143.